Applicant, as named in the Orange Book

Deciphera Pharms

Next listed expiry: Qinlock on 6 Oct 2042. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Qinlock ripretinib	ripretinib	213973	6 Oct 2042	patent, carve-out possible
Romvimza · 3 strengths vimseltinib	vimseltinib	219304	30 Apr 2045	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.